AtriCure to Present at the 9th Annual JMP Securities Healthcare Conference
JMP Securities Healthcare Conference 2014
WEST CHESTER, Ohio -- May 28, 2014
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device
provider, today announced that it will present at the 9^th Annual JMP
Securities Healthcare Conference at The Westin New York Grand Central on
Tuesday, June 24, 2014. Management is scheduled to present at1:30 p.m.
A live audio webcast and replay of the presentation will be available for 90
days following the presentation at http://wsw.com/webcast/jmp24/ATRC.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in patients
undergoing certain open concomitant procedures. AtriCure’s AtriClip Left
Atrial Appendage (LAA) exclusion device is the most widely implanted device
for LAA management worldwide.The company believes cardiothoracic surgeons are
adopting its ablation and LAA management devices for the treatment of Afib and
reduction of Afib related complications such as stroke. Afib affects more than
5.5 million people worldwide.
Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
Investor Relations Contact
Lynn Pieper, 415-202-5678
Press spacebar to pause and continue. Press esc to stop.